Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS
Abstract
:1. Introduction to Systemic Lupus Erythematosus (SLE)
2. Challenges in the Management of SLE
3. Measurement of Disease Activity in SLE
4. Development and Characteristics of SLE-DAS
5. Comparison of SLE-DAS and Other SLE Activity Indices
6. The Association of SLE-DAS with Health-Related Quality of Life (HRQoL)
7. SLE-DAS as a Predictor for Hospitalization Risk in SLE
8. Assessing SLE Disease Activity during Pregnancy Using SLE-DAS
9. SLE-DAS as a Treatment Target for SLE
10. Limitations and Future Perspectives
11. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Tian, J.; Zhang, D.; Yao, X.; Huang, Y.; Lu, Q. Global epidemiology of systemic lupus erythematosus: A comprehensive systematic analysis and modelling study. Ann. Rheum. Dis. 2023, 82, 351–356. [Google Scholar] [CrossRef] [PubMed]
- Carter, E.E.; Barr, S.G.; Clarke, A.E. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat. Rev. Rheumatol. 2016, 12, 605–620. [Google Scholar] [CrossRef] [PubMed]
- Weckerle, C.E.; Niewold, T.B. The unexplained female predominance of systemic lupus erythematosus: Clues from genetic and cytokine studies. Clin. Rev. Allergy Immunol. 2011, 40, 42–49. [Google Scholar] [CrossRef] [PubMed]
- Dörner, T.; Furie, R. Novel paradigms in systemic lupus erythematosus. Lancet 2019, 393, 2344–2358. [Google Scholar] [CrossRef] [PubMed]
- Fanouriakis, A.; Tziolos, N.; Bertsias, G.; Boumpas, D.T. Update οn the diagnosis and management of systemic lupus erythematosus. Ann. Rheum. Dis. 2021, 80, 14–25. [Google Scholar] [CrossRef] [PubMed]
- Arnaud, L.; Tektonidou, M.G. Long-term outcomes in systemic lupus erythematosus: Trends over time and major contributors. Rheumatology 2020, 59 (Suppl. S5), v29–v38. [Google Scholar] [CrossRef] [PubMed]
- Lee, Y.H.; Choi, S.J.; Ji, J.D.; Song, G.G. Overall and cause-specific mortality in systemic lupus erythematosus: An updated meta-analysis. Lupus 2016, 25, 727–734. [Google Scholar] [CrossRef]
- Parra Sánchez, A.R.; Voskuyl, A.E.; van Vollenhoven, R.F. Treat-to-target in systemic lupus erythematosus: Advancing towards its implementation. Nat. Rev. Rheumatol. 2022, 18, 146–157. [Google Scholar] [CrossRef]
- Romero-Diaz, J.; Isenberg, D.; Ramsey-Goldman, R. Measures of adult systemic lupus erythematosus: Updated version of British Isles Lupus Assessment Group (BILAG 2004), European Consensus Lupus Activity Measurements (ECLAM), Systemic Lupus Activity Measure, Revised (SLAM-R), Systemic Lupus Activity Questionnaire for Population Studies (SLAQ), Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K), and Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI). Arthritis Care. Res. 2011, 63 (Suppl. S1), S37–S46. [Google Scholar]
- Hay, E.M.; Bacon, P.A.; Gordon, C.; Isenberg, D.A.; Maddison, P.; Snaith, M.L.; Symmons, D.P.; Viner, N.; Zoma, A. The BILAG index: A reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q. J. Med. 1993, 86, 447–458. [Google Scholar]
- Vitali, C.; Bencivelli, W.; Isenberg, D.A.; Smolen, J.S.; Snaith, M.L.; Sciuto, M.; Neri, R.; Bombardieri, S. Disease activity in systemic lupus erythematosus: Report of the Consensus Study Group of the European Workshop for Rheumatology Research. II. Identification of the variables indicative of disease activity and their use in the development of an activity score. The European Consensus Study Group for Disease Activity in SLE. Clin. Exp. Rheumatol. 1992, 10, 541–547. [Google Scholar]
- Gladman, D.; Ginzler, E.; Goldsmith, C.; Fortin, P.; Liang, M.; Urowitz, M.; Bacon, P.; Bombardieri, S.; Hanly, J.; Hay, E.; et al. The development and initial validation of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology damage index for systemic lupus erythematosus. Arthritis Rheum. 1996, 39, 363–369. [Google Scholar] [CrossRef] [PubMed]
- Gladman, D.D.; Ibañez, D.; Urowitz, M.B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 2002, 29, 288–291. [Google Scholar] [PubMed]
- Petri, M.; Kim, M.Y.; Kalunian, K.C.; Grossman, J.; Hahn, B.H.; Sammaritano, L.R.; Lockshin, M.; Merrill, J.T.; Belmont, H.M.; Askanase, A.D.; et al. Combined oral contraceptives in women with systemic lupus erythematosus. N. Engl. J. Med. 2005, 353, 2550–2558. [Google Scholar] [CrossRef] [PubMed]
- Jesus, D.; Matos, A.; Henriques, C.; Zen, M.; Larosa, M.; Iaccarino, L.; Da Silva, J.A.P.; Doria, A.; Inês, L.S. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): A new SLE continuous measure with high sensitivity for changes in disease activity. Ann. Rheum. Dis. 2019, 78, 365–371. [Google Scholar] [CrossRef] [PubMed]
- Carter, L.M.; Gordon, C.; Yee, C.S.; Bruce, I.; Isenberg, D.; Skeoch, S.; Vital, E.M. Easy-BILAG: A new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology 2022, 61, 400–4015. [Google Scholar] [CrossRef] [PubMed]
- Mathew, A.; Chengappa, K.G.; Shah, S.; Negi, V.S. SLE-DAS: Ready for routine use? Ann. Rheum. Dis. 2020, 79, e116. [Google Scholar] [CrossRef] [PubMed]
- Lai, N.S.; Lu, M.C.; Chang, H.H.; Lo, H.C.; Hsu, C.W.; Huang, K.Y.; Tung, C.H.; Hsu, B.B.; Wu, C.H.; Koo, M. A comparison of the correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with health-related quality of life. J. Clin. Med. 2021, 10, 2137. [Google Scholar] [CrossRef]
- Saraiva, L.; Cunha, R.N.; Jesus, D.; Gatto, M.; Zen, M.; Iaccarino, L.; da Silva, J.A.P.; Doria, A.; Inês, L.S. The SLE-DAS provides an accurate and feasible flare tool in the clinical setting: A validation study. Rheumatology 2023, kead353. [Google Scholar] [CrossRef]
- Leosuthamas, P.; Narongroeknawin, P.; Chaiamnuay, S.; Asavatanabodee, P.; Pakchotanon, R. Performance of systemic lupus erythematosus responder index for detecting clinician-rated responders in patients with active systemic lupus erythematosus. Int. J. Rheum. Dis. 2023, 26, 667–672. [Google Scholar] [CrossRef]
- Murphy, C.L.; Yee, C.S.; Gordon, C.; Isenberg, D. From BILAG to BILAG-based combined lupus assessment-30 years on. Rheumatology 2016, 55, 1357–1363. [Google Scholar] [CrossRef] [PubMed]
- Symmons, D.P.; Coppock, J.S.; Bacon, P.A.; Bresnihan, B.; Isenberg, D.A.; Maddison, P.; McHugh, N.; Snaith, M.L.; Zoma, A.S. Development and assessment of a computerized index of clinical disease activity in systemic lupus erythematosus. Members of the British Isles Lupus Assessment Group (BILAG). Q. J. Med. 1988, 69, 927–937. [Google Scholar] [PubMed]
- Isenberg, D.A.; Rahman, A.; Allen, E.; Farewell, V.; Akil, M.; Bruce, I.N.; D’Cruz, D.; Griffiths, B.; Khamashta, M.; Maddison, P.; et al. Development and initial validation of an updated version of the British Isles Lupus Assessment Group’s disease activity index for patients with systemic lupus erythematosus. Rheumatology 2005, 44, 902–906. [Google Scholar] [CrossRef] [PubMed]
- Aringer, M.; Leuchten, N. Assessment-Tools für den systemischen Lupus erythematodes [Assessment tools for systemic lupus erythematosus]. Z. Fur Rheumatol. 2023, 82, 361–367. [Google Scholar] [CrossRef] [PubMed]
- Parodis, I.; Studenic, P. Patient-reported outcomes in systemic lupus erythematosus. can lupus patients take the driver’s seat in their disease monitoring? J. Clin. Med. 2022, 11, 340. [Google Scholar] [CrossRef] [PubMed]
- Yazdany, J. Health-related quality of life measurement in adult systemic lupus erythematosus: Lupus Quality of Life (LupusQoL), Systemic Lupus Erythematosus-Specific Quality of Life Questionnaire (SLEQOL), and Systemic Lupus Erythematosus Quality of Life Questionnaire (L-QoL). Arthritis. Care. Res. 2011, 63 (Suppl. S11), S413–S419. [Google Scholar]
- McElhone, K.; Abbott, J.; Shelmerdine, J.; Bruce, I.N.; Ahmad, Y.; Gordon, C.; Peers, K.; Isenberg, D.; Ferenkeh-Koroma, A.; Griffiths, B.; et al. Development and validation of a disease-specific health-related quality of life measure, the LupusQol, for adults with systemic lupus erythematosus. Arthritis Rheum. 2007, 57, 972–979. [Google Scholar] [CrossRef]
- Onishi, A.; Tsuji, H.; Takase, Y.; Nakakubo, Y.; Iwasaki, T.; Kozuki, T.; Yoshida, T.; Shirakashi, M.; Onizawa, H.; Hiwa, R.; et al. Comparisons of SLE-DAS and SLEDAI-2K and classification of disease activity based on the SLE-DAS with reference to patient-reported outcomes. Rheumatology 2023, kead132. [Google Scholar] [CrossRef]
- Leong, K.P.; Kong, K.O.; Thong, B.Y.; Koh, E.T.; Lian, T.Y.; The, C.L.; Cheng, Y.K.; Chng, H.H.; Badsha, H.; Law, W.G.; et al. Development and preliminary validation of a systemic lupus erythematosus-specific quality-of-life instrument (SLEQOL). Rheumatology 2005, 44, 1267–1276. [Google Scholar] [CrossRef]
- Ferreira, P.L.; Cunha, R.N.; Macieira, C.; Fontes, T.; Inês, L.S.; Maduro, A.; Martins, A.; Rajão, F.; Furtado, C.; Barcelos, A. Creation and validation of the European Portuguese version of the Systemic Lupus Erythematous Quality of Life questionnaire. Int. J. Environ. Res. Public Health 2023, 20, 897. [Google Scholar] [CrossRef]
- Jiang, H.Z.; Lin, Z.G.; Li, H.J.; Du, Q.; Tian, W.; Wang, S.Y.; Guan, S.Q.; Mei, Y.F. The Chinese version of the SLEQOL is a reliable assessment of health-related quality of life in Han Chinese patients with systemic lupus erythematosus. Clin. Rheumatol. 2018, 37, 151–160. [Google Scholar] [CrossRef] [PubMed]
- Elera-Fitzcarrald, C.; Fuentes, A.; González, L.A.; Burgos, P.I.; Alarcón, G.S.; Ugarte-Gil, M.F. Factors affecting quality of life in patients with systemic lupus erythematosus: Important considerations and potential interventions. Expert Rev. Clin. Immunol. 2018, 14, 915–931. [Google Scholar] [CrossRef] [PubMed]
- Shi, Y.; Li, M.; Liu, L.; Wang, Z.; Wang, Y.; Zhao, J.; Wang, Q.; Tian, X.; Li, M.; Zeng, X. Relationship between disease activity, organ damage and health-related quality of life in patients with systemic lupus erythematosus: A systemic review and meta-analysis. Autoimmun. Rev. 2021, 20, 102691. [Google Scholar] [CrossRef] [PubMed]
- Jesus, D.; Larosa, M.; Henriques, C.; Matos, A.; Zen, M.; Tomé, P.; Alves, V.; Costa, N.; Le Guern, V.; Iaccarino, L.; et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann. Rheum. Dis. 2021, 80, 1568–1574. [Google Scholar] [CrossRef] [PubMed]
- Lu, M.C.; Hsu, C.W.; Koo, M.; Lai, N.S. Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: A prospective cohort study. Clin. Exp. Rheumatol. 2023, 41, 1409–1416. [Google Scholar] [CrossRef] [PubMed]
- Wang, C.L.; Koo, M.; Hsu, C.W.; Lu, M.C. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study. Lupus 2023, 32, 864–872. [Google Scholar] [CrossRef]
- Buyon, J.P.; Kalunian, K.C.; Ramsey-Goldman, R.; Petri, M.A.; Lockshin, M.D.; Ruiz-Irastorza, G.; Khamashta, M. Assessing disease activity in SLE patients during pregnancy. Lupus 1999, 8, 677–684. [Google Scholar] [CrossRef] [PubMed]
- Larosa, M.; Costedoat-Chalumeau, N.; Guettrot-Imbert, G.; Le Guern, V.; Morel, N.; Jesus, D.; Iaccarino, L.; Inês, L.; Doria, A. SLE-DAS in the first trimester of gestation predicts maternal lupus flares later in pregnancy. Front. Pharmacol. 2021, 12, 660123. [Google Scholar] [CrossRef]
- Franklyn, K.; Lau, C.S.; Navarra, S.V.; Louthrenoo, W.; Lateef, A.; Hamijoyo, L.; Wahono, C.S.; Chen, S.L.; Jin, O.; Morton, S.; et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann. Rheum. Dis. 2016, 75, 1615–1621. [Google Scholar] [CrossRef]
- Kandane-Rathnayake, R.; Golder, V.; Louthrenoo, W.; Chen, Y.H.; Cho, J.; Lateef, A.; Hamijoyo, L.; Luo, S.F.; Wu, Y.J.J.; Navarra, S.V.; et al. Lupus low disease activity state and remission and risk of mortality in patients with systemic lupus erythematosus: A prospective, multinational, longitudinal cohort study. Lancet Rheumatol. 2022, 4, E822–E830. [Google Scholar] [CrossRef]
- Ugarte-Gil, M.F.; Gamboa-Cardenas, R.V.; Reátegui-Sokolova, C.; Pimentel-Quiroz, V.R.; Medina, M.; Elera-Fitzcarrald, C.; Zevallos, F.; Pastor-Asurza, C.A.; Lofland, J.; Zazzetti, F.; et al. LLDAS (lupus low disease activity state) and/or remission are associated with less damage accrual in patients with systemic lupus erythematosus from a primarily Mestizo population: Data from the Almenara Lupus Cohort. Lupus Sci. Med. 2022, 9, e000616. [Google Scholar] [CrossRef] [PubMed]
- Morand, E.; Pike, M.; Merrill, J.T.; van Vollenhoven, R.; Werth, V.P.; Hobar, C.; Delev, N.; Shah, V.; Sharkey, B.; Wegman, T.; et al. Deucravacitinib, a tyrosine kinase 2 inhibitor, in systemic lupus erythematosus: A phase II, randomized, double-blind, placebo-controlled trial. Arthritis Rheumatol. 2023, 75, 242–252. [Google Scholar] [CrossRef] [PubMed]
- Morand, E.F.; Abreu, G.; Furie, R.A.; Golder, V.; Tummala, R. Lupus low disease activity state attainment in the phase 3 TULIP trials of anifrolumab in active systemic lupus erythematosus. Ann. Rheum. Dis. 2023, 82, 639–645. [Google Scholar] [CrossRef] [PubMed]
- Abdelhady, E.I.; Rabie, M.; Hassan, R.A. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). Clin. Rheumatol. 2021, 40, 4553–4558. [Google Scholar] [CrossRef] [PubMed]
- Assunção, H.; Jesus, D.; Larosa, M.; Henriques, C.; Matos, A.; Le Guern, V.; Rubiño, F.; da Silva, J.A.P.; Rua-Figueroa, I.; Costedoat-Chalumeau, N.; et al. Definition of low disease activity state based on the SLE-DAS: Derivation and validation in a multicentre real-life cohort. Rheumatology 2022, 61, 3309–3316. [Google Scholar] [CrossRef] [PubMed]
- Cunha, R.N.; Saraiva, L.; Jesus, D.; Doria, A.; da Silva, J.P.; Inês, L.S. Predictors of flare in SLE patients fulfilling lupus low disease activity state: A cohort study of 292 patients with 36-month follow-up. Rheumatology 2023, 62, 3627–3635. [Google Scholar] [CrossRef] [PubMed]
- van Vollenhoven, R.F.; Bertsias, G.; Doria, A.; Isenberg, D.; Morand, E.; Petri, M.A.; Pons-Estel, B.A.; Rahman, A.; Ugarte-Gil, M.F.; Voskuyl, A.; et al. 2021 DORIS definition of remission in SLE: Final recommendations from an international task force. Lupus Sci. Med. 2021, 8, e000538. [Google Scholar] [CrossRef] [PubMed]
- Jesus, D.; Matos, A.; Henriques, C.; Zen, M.; Doria, A.; Inês, L.S. Response to: ‘SLE-DAS: Ready for routine use’ by Mathew et al. Ann. Rheum. Dis. 2020, 79, e117. [Google Scholar] [CrossRef]
- Inês, L.S.; Fredi, M.; Jesus, D.; Shumilova, A.; Franceschini, F.; Vital, E.M. What is the best instrument to measure disease activity in SLE?—SLE-DAS vs Easy BILAG. Autoimmun. Rev. 2023, 103428. [Google Scholar] [CrossRef]
- Ocampo-Piraquive, V.; Nieto-Aristizábal, I.; Cañas, C.A.; Tobón, G.J. Mortality in systemic lupus erythematosus: Causes, predictors and interventions. Expert. Rev. Clin. Immunol. 2018, 14, 1043–1053. [Google Scholar] [CrossRef]
- Shin, J.I.; Lee, K.H.; Park, S.; Yang, J.W.; Kim, H.J.; Song, K.; Lee, S.; Na, H.; Jang, Y.J.; Nam, J.Y.; et al. Systemic lupus erythematosus and lung involvement: A comprehensive review. J. Clin. Med. 2022, 11, 6714. [Google Scholar] [CrossRef]
- Schwartzman-Morris, J.; Putterman, C. Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin. Dev. Immunol. 2012, 2012, 604892. [Google Scholar] [CrossRef]
- Ramírez Sepúlveda, J.I.; Bolin, K.; Mofors, J.; Leonard, D.; Svenungsson, E.; Jönsen, A.; Bengtsson, C.; DISSECT consortium; Nordmark, G.; Rantapää Dahlqvist, S..; et al. Sex differences in clinical presentation of systemic lupus erythematosus. Biol. Sex Diff. 2019, 10, 60. [Google Scholar] [CrossRef] [PubMed]
Goal | Index Compared | Results | Number of Patients (Ethnicity) | Reference Number |
---|---|---|---|---|
Clinically meaningful changes | ΔSLE-DAS ≥ 1.72 and ΔSLEDAI-2K ≥ 4 | ΔSLE-DAS ≥ 1.72 sensitivity 82.1%, specificity 96.9%; ΔSLEDAI-2K ≥ 4 sensitivity 44.8%, specificity 96.5%; p < 0.0005. | 196 (validation cohort) (94.4% Caucasian) | [15] |
Identification of flare | ΔSLE-DAS ≥ 1.72, classic-SELENA Flare Index (c-SFI), revised-SFI (r-SFI), and SLEDAI-2K (score increase ≥ 4) | Sensitivity: SLE-DAS 97.1%, c-SFI 88.4%, r-SFI 88.4%, SLEDAI-2K 56.5%. Specificity: SLE-DAS 97.3%, c-SFI 98.1%, r-SFI 96.8%, SLEDAI-2K 99.2%. Result of ROC analysis: ΔSLE-DAS ≥ 1.72 is best. | 442 (95.7% Caucasian) | [19] |
Classified responders vs. non-responders | SLEDAI-2K responder index-50 (SRI-50), SLE responder index-4 (SRI-4), substituting SLEDAI-2K with SRI-50 in SRI-4 (SRI-4(50)), ΔSLE-DAS ≥ 1.72, and BICLA | No differences. | 27 (Asian) | [20] |
Association with health-related quality of life (LupusQoL) | SLEDAI-2K and SLE-DAS | No differences. | 333 (Asian) | [18] |
Association with health-related quality of life (LupusPRO) | SLEDAI-2K and SLE-DAS | No differences. | 335 (Asian) | [28] |
Predict risk of hospitalization | SLE disease activity classified by SLEDAI-2K and SLE-DAS | SLE-DAS, but not SLEDAI-2K, was associated with an increased risk for all-cause and SLE-related hospitalization. | 326 (Asian) | [35] |
Predict frequency of hospitalization | SLE disease activity classified by SLEDAI-2K and SLE-DAS | Both SLE-DAS and SLEDAI-2K were associated with frequency of all-cause hospitalization. SLE-DAS, but not SLEDAI-2K, was associated with frequency of SLE-related hospitalization. | 324 (Asian) | [36] |
Predict maternal flare | SLE-DAS and SLE-pregnancy disease activity index (SLEPDAI) | Both SLE-DAS and SLEPDAI predicted maternal flares and adverse pregnancy outcomes. | 158 (White 78.5%, Black 13.3%, Asian 6.9%) | [38] |
Definitions of clinical remission | SLE-DAS Boolean-based remission criteria, SLE-DAS index-based remission criteria, and DORIS definition of remission | Both the SLE-DAS Boolean-based remission criteria and SLE-DAS index-based remission criteria were comparable with the DORIS clinical remission criteria. | 969 (validation cohorts) (White 67.4%, Black 15.5%, Hispanic 18.3%) | [34] |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Koo, M.; Lu, M.-C. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS. Medicina 2023, 59, 2097. https://doi.org/10.3390/medicina59122097
Koo M, Lu M-C. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS. Medicina. 2023; 59(12):2097. https://doi.org/10.3390/medicina59122097
Chicago/Turabian StyleKoo, Malcolm, and Ming-Chi Lu. 2023. "Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS" Medicina 59, no. 12: 2097. https://doi.org/10.3390/medicina59122097